V. Functional Interactions of MAS-Related
Abstract--Signaling by heptahelical G proteincoupled receptors (GPCR) regulates many vital body functions. Consequently, dysfunction of GPCR signaling leads to pathologic states, and approximately 30% of all modern clinical drugs target GPCR. One decade ago, an entire new GPCR family was discovered, which was recently named MAS-related G protein-coupled receptors (MRGPR) by the HUGO Gene Nomenclature Committee. The MRGPR family consists of ∼40 members that are grouped into nine distinct subfamilies (MRGPRA to -H and -X) and are predominantly expressed in primary sensory neurons and mast cells. All members are formally still considered "orphan" by the Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology. However, several distinct peptides and amino acids are discussed as potential ligands, including b-alanine, angiotensin-(1-7), alamandine, GABA, cortistatin-14, and cleavage products of proenkephalin, proopiomelanocortin, prodynorphin, or proneuropeptide-FF-A. The full spectrum of biologic roles of all MRGPR is still ill-defined, but there is evidence pointing to a role of distinct MRGPR subtypes in nociception, pruritus, sleep, cell proliferation, circulation, and mast cell degranulation. This review article summarizes findings published in the last 10 years on the phylogenetic relationships, pharmacology, signaling, physiology, and agonist-promoted regulation of all MRGPR subfamilies. Furthermore, we highlight interactions between MRGPR and other hormonal systems, paying particular attention to receptor multimerization and morphine tolerance. Finally, we discuss the challenges the field faces presently and emphasize future directions of research.
I. Introduction
G protein-coupled receptors (GPCR), also known as seven-transmembrane domain receptors, constitute a large protein family that senses a plethora of distinct physical and chemical stimuli (biogenic amines, amino acids, ions, lipids, nucleotides, peptides, proteins, light, odorants, and pheromones) outside the cell. Upon GPCR activation, a host of intracellular signaling proteins (enzymes, transcription factors, ion channels) are engaged, affecting vital cellular and organismal functions, such as cell proliferation, differentiation, development, survival, circulation, metabolism, neuronal signal transmission, and sensory perception. Approximately 800 putative GPCR have been identified in humans and more than 300 of them are nonodorant receptors (Fredriksson et al., 2003) . Interestingly, endogenous or natural exogenous ligands have not been identified for ;100 of the GPCR identified so far, suggesting that many biologic functions of GPCR may not have been discovered yet (Davenport et al., 2013) . It is reasonable to assume that these "orphan" GPCR have an immense therapeutic potential, because ;30% of all clinically relevant drugs already target GPCR directly or modulate their cognate signaling pathways (Overington et al., 2006) . Hence, in recent years, considerable efforts have been undertaken to identify endogenous ligands of "orphan" GPCR by highthroughput screening strategies. As a result of one of these efforts, Lembo and coworkers (2002) reported a group of human "orphan" receptors that are activated by proenkephalin (PENK) cleavage products of the bovine adrenal medulla (BAM) peptide family. The authors called these receptors sensory neuron-specific G protein-coupled receptors (SNSR) because of their restricted expression pattern in primary sensory ABBREVIATIONS: BAM, bovine adrenal medulla; CAP, capsaicin; CCR2, chemokine receptors 2; CFA, complete Freund's adjuvant; CGRP, calcitonin gene-related peptide; CHO, Chinese hamster ovary; D-APV, D-(2)-2-amino-5-phosphonopentanoic acid; DOP, d-OR; DRG, dorsal root ganglia; ERK, extracellular signal-regulated kinase; GFP, green fluorescent protein; GPCR, G protein-coupled receptors; 1, 2, 3, phenyl]-2,6-dioxo-7H-purine-7-acetamide, 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide; HEK, human embryonic kidney; MK-801, (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine; MOP, m-OR; Mrg, MAS-related gene; MRGPR, MAS-related G protein-coupled receptors; MSH, melanocyte stimulating hormone; NC-IUPHAR, Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology; NFAT, nuclear factor of activated T cells; NMDA, N-methyl-D-aspartate; nNOS, neuronal nitric oxide synthetase; NPAF, neuropeptide AF; NPFF, neuropeptide FF; OR, opioid receptors; PAR, protease-activated receptors; PENK, proenkephalin; PIP 2 , phosphatidylinositol-3,4-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; PTX, pertussis toxin; SNSR, sensory neuron-specific receptors; TrkA, neurotrophic tyrosin kinase receptor 1; TRP, transient receptor potential cation channel; TRPA, TRP ankyrin; TRPM, TRP melastatin 8; TRPV, TRP vanilloid 1; YM58483, -1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide.
MAS-Related G Protein-Coupled Receptors 571 neurons and postulated a role for SNSR in pain perception. Shortly before, Dong and colleagues (2001) compared cDNA libraries from wild-type mice and from mice lacking the transcription factor neurogenin 1. Mice without functional neurogenin 1 fail to develop the neurotrophic tyrosine kinase receptor 1 (TrkA)-positive subclass of dorsal root ganglia (DRG) and trigeminal ganglia neurons that detect painful stimuli, so called TrkA + nociceptors (Ma et al., 1999) . Thus, the authors postulated that genes found in the library of wild-type mice, but not in neurogenin 1-deficient mice, should be specific for TrkA + nociceptors. By this approach, the authors discovered an entire new family of selectively expressed GPCR and named these proteins MAS-related genes (Mrg), because of their homology to the oncogenic GPCR MAS1. The Mrg family in rodents and humans comprises ;40 members that can be divided into several subfamilies. It soon turned out that one of these subfamilies, the MrgX family, is identical to the SNSR proteins (Lembo et al., 2002) , such that the same receptor proteins were given two different names. Even more confusing, the rat MrgC/SNSR was named after its proposed cognate ligand BAM peptide-activated receptor with nonopioid activity, and MRG is also used as an abbreviation for mortality factor on chromosome 4-related genes [mortality factor on chromosome 4/MRG functions in aging are reviewed elsewhere (Chen et al., 2010a) ], a group of proteins distinct from the GPCR superfamily. Thus, inconsistencies in the nomenclature developed over the last decade may have contributed to confusions in the field. To overcome this problem, the HUGO Gene Nomenclature Committee now refers to Mrg/SNSR proteins as MAS-related G protein-coupled receptors (MRGPR) (www.genename.org). So far, a total of 38 genes encoding MRGPR proteins has been listed in National Center for Biotechnology Information databases (orthologous proteins from distinct mammalian species are counted as one member, see Fig. 1 and Table 1 ). Therefore, to the best of our knowledge, MRGPR represent the nonodorant GPCR family with the largest number of members known so far. At present, MRGPR are arranged in nine subfamilies, designated by capital letters, whereas individual subtypes are indicated by numbers. For instance, the MRGPR subtype 1 of subfamily X, originally termed MrgX1 (according to Dong et al., 2001) or SNSR4 (according to Lembo et al., 2002) , is now officially called MRGPRX1. This nomenclature is also recognized by Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR; Davenport et al., 2013) and is recommended for use to improve scientific communication.
Since their first description, considerable efforts have been undertaken to characterize MRGPR in terms of ligand binding profile, regulation, signaling cascades, and physiologic effects. Significant progress has been made recently and, thus, several MRGPR members emerged as most appealing pharmacological targets for analgesic, antipruritogenic, and antihypertensive therapies. However, at the same time, advances in our understanding of the physiology and pathophysiology of MRGPR are hampered by a complex phylogeny, redundancy in ligand binding, and multifaceted functions. This review is an attempt to summarize our present knowledge about the MRGPR family and to point out current caveats. We present an overview of MRGPR genetics, including phylogeny and evolution, and of pharmacologic and physiologic details of each MRGPR subfamily. Finally, we will highlight agonist-induced MRGPR regulation and interactions with other GPCR families identified so far.
II. Genes Encoding MAS-Related G Protein-Coupled Receptors

A. Preface
MRGPR-encoding genes have been detected in mammals, including rodents, Canis lupus, Bos taurus, and primates. No MRGPR genes have been identified in lower vertebrates so far, probably because of less advanced gene sequencing and annotation processes of lower vertebrate genomes. Only one MRGPR member was annotated in the genome of birds: Solely the MRGPRH was found in Gallus gallus. The GPCR superfamily is divided based on sequence homology into class A to F. According to the existence of several conserved motifs, for instance the NPxxY motif in transmembrane domain seven, the MRGPR family is assigned to the rhodopsin-like class A (Dong et al., 2001; Lembo et al., 2002; Fredriksson et al., 2003; Katritch et al., 2013) . The rhodopsin-like GPCR class A can be further subdivided into four groups designated a to d. MRGPR belong to the d-group of class A, which also comprises glycohormone, purinergic and the very large family of olfactory receptors, with glycohormone receptors being the receptor family most closely related to the MRGPR family (Dong et al., 2001; Lembo et al., 2002; Fredriksson et al., 2003; Katritch et al., 2013) .
B. Phylogeny
The mammalian family of MRGPR can be subdivided into nine separate subfamilies (A-H and X) because of sequence similarities (see Fig. 1 and Table 1 ). Subfamilies A, B, C, and H exist only in rodents, whereas subfamily X is specific to primates including humans, macaque, and rhesus monkey (Dong et al., 2001; Lembo et al., 2002; Zylka et al., 2003; Zhang et al., 2005; Burstein et al., 2006) . In contrast, subfamilies D to G are conserved in different mammalian species, including rodents and primates (Dong et al., 2001; Lembo et al., 2002; Zylka et al., 2003) .
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The MRGPRA subfamily composition differs considerably among rodents. Although only one gene is found in rats, mice harbor 18 protein-encoding MRGPRA genes as well as several pseudogenes (Dong et al., 2001; Zylka et al., 2003) . The MRGPRB subfamily comprises seven protein-encoding genes in rats, nine in mice, and several pseudogenes in both species (Dong et al., 2001; Zylka et al., 2003) . According to Zylka et al. (2003) , a further subdivision of MRGPRB genes into the subgroups B2, B4, and B8 is procurable and reflects the basic set of MRGPRB in other rodent species, such as gerbil. The MRGPRC subfamily consists of only one gene in rats and one protein-encoding gene in addition to 13 pseudogenes in mice (Han et al., 2002; Zylka et al., 2003) . The MRGPRD subfamily comprises only one protein-encoding gene per species (Dong et al., 2001; Lembo et al., 2002; Zylka et al., 2003) . Just like MRGPRD, MRGPRE to -H subtypes exhibit only one protein-encoding gene per species (Zylka et al., 2003) . The MRGPRX subfamily was originally reported to consist of four distinct genes that are all located on chromosome 11p15.1 in humans (Dong et al., 2001) . Three of the four receptors discovered earlier were identified independently by other researchers, and three additional receptors were isolated from the same laboratory (Lembo et al., 2002) , resulting in a total of seven distinct MRGPRX receptors. However, three of the original putative MRGPRX members (SNSR2, have not yet been listed by NC-IUPHAR, most likely because these receptors are up to 98% identical to the listed MRGPRX and, thus, probably represent polymorphisms but not distinct subtypes. Hence, four distinct MRGPRX proteins (MRGPRX1 to -4) are currently listed by NC-IUPHAR and will be reviewed herein. Table 2 provides an overview of the identities and relationships of all MRGPRX members published and officially listed so far. A phylogenetic tree of all 38 MRGPR members from the nine MRGPR subfamilies (A-H, X) of mice (m), rat (r), human (h), and rhesus monkey (Rh) was computed using Geneious 7 (Biomatters, Auckland, New Zealand; Blosum62 cost matrix, Jukes-Cantor genetic distance model, Neighbor-Joining tree build method). GeneID of MRGPR genes and their aliases are given in Table 1 . The scale bar indicates amino acid substitutions per site. Deeper insights into the phylogenetic relationship of the human MRGPR and other GPCR families are provided within the excellent articles of Fredriksson or Katritch (Fredriksson et al., 2003; Katritch et al., 2013) .
MAS-Related G Protein-Coupled Receptors
C. Expression
The majority of MRGPR is expressed in isolectin B4-positive small-diameter somatosensory afferents, which represent about half of the nociceptors per DRG (Snider and McMahon, 1998) . All MRGPRA, MRGPRC to -H, and MRGPRX members, as well as the MRGPRB4 and -5 subtype, can be subsumed to be expressed in isolectin B4-positive DRG neurons (Dong et al., 2001; Robas et al., 2003; Zylka et al., 2003; Zhang et al., 2005; Tatemoto et al., 2006; Cox et al., 2008; Liu et al., 2009) . None of the remaining MRGPRB members have been detected in primary sensory neurons so far. However, high amounts of MRGPRB3 and -8 transcripts, as well as lower copy numbers of the remaining three rat MRGPRB members, were measured in rat peritoneal mast cells, whereas transcripts of MRGPRA or -C were not present in these cells (Tatemoto et al., 2006) . Recently, MRGPRX1 and -2 expression was also shown in human mast cells (Tatemoto et al., 2006; Subramanian et al., 2011b; Solinski et al., 2013) . Thus, human MRGPRX mirror the expression pattern of rodent MRGPRB and -A/C, lending support to the current theory of MRGPR evolution, implying that MRGPRX1 and -2 genes inherited promoter elements from ancestral MRGPRB and -A/C genes (for details see section II.D). The initial discovery of the MRGPR family pointed to a selective expression of MRGPR in primary sensory neurons derived from the TrkA + population (Dong et al., 2001) . Perinatally, this results in a largely overlapping MRGPRA to -D expression in the same population of neurons (Dong et al., 2001; Zylka et al., 2003; Liu et al., 2008) . After birth, TrkA expression ceases in roughly half of the formerly TrkA + neurons (Molliver et al., 1997) . Instead of TrkA, these cells start to express c-ret, the receptor of the glial-derived neurotrophic factor (Molliver et al., 1997) . In adulthood, expression of all MRGPR is maintained in c-ret + , but not in the remaining TrkA + neurons (Dong et al., 2001; Zylka et al., 2003; Liu et al., 2008) . Interestingly, despite the largely overlapping expression pattern of all MRGPR in perinatal primary sensory neurons, in adulthood most MRGPR subtypes are not coexpressed in the same c-ret + population and exhibit a compartmentalized expression pattern in distinct subpopulations (Dong et al., 2001; Zylka et al., 2003; Liu et al., 2008) . Notably, these expression patterns are not identical in mice and rats, suggesting variations in the physiologic roles of distinct MRGPR in rodents. The analysis of transcriptional pathways responsible for expression of different MRGPR in distinct DRG populations in mice revealed that expression of MRGPRA to -D initially depends on the activity of the runt-related transcription factor 1, explaining the overlapping expression pattern in embryonic neurons (Liu et al., 2008) . During postnatal development, runtrelated transcription factor 1 suppresses MRGPRA to -C, but not MRGPRD expression, through its inhibitory C-terminal domain, leading to the segregation of murine MRGPRD and MRGPRA to -C expression in adolescence. Furthermore, the authors found that the transcription factor Smad4 is indispensable for MRGPRB4 expression, but does not affect expression of other MRGPR subtypes (Liu et al., 2008) . The distinct expression pattern of MRGPR in adulthood led to the assumption that neuronal subpopulations characterized by their MRGPR expression pattern might have distinct functions. In line with this hypothesis, MRGPRB4-or MRGPRD-positive primary sensory neurons in mice obtain distinct somatosensory input from different skin areas (Zylka et al., 2005; Liu et al., 2007) , whereas MRGPRA3 expression specifies neurons that induce itch without transducing nociceptive cues (Han et al., 2013) .
In addition to the highly selective expression of several MRGPR in small-diameter primary sensory neurons and the aforementioned expression of some MRGPR in mast cells, MRGPRD to -H and MRGPRX2 expression was also found in other tissues. Significant mRNA levels of MRGPRD were detected in urinary bladder, testis, uterus, and arteries (Shinohara et al., 2004) . MRGPRE transcripts were also monitored in medium-and large-diameter neurons of human DRG sections (Zhang et al., 2005) and in other areas of the central nervous system, including cerebral cortex, hippocampus, spinal cord, and cerebellum, as well as in human, mouse, and rat placenta (Zhang et al., 2005; Milasta et al., 2006) . MRGPRE and MRGPRF are also expressed in enteric neurons (Avula et al., 2011) , belonging to one of the main divisions of the autonomic nervous system that regulates gastrointestinal functions. In accordance with these findings, transcripts of MRGPRF, formally known as rat thoracic aorta receptor, were detected in small and large intestine (Ross et al., 1990) . More precisely, MRGPRE and MRGPRF proteins were detected in both myenteric and submucosal neurons, the latter showing coexpression of both receptors in 30-50% of neurons analyzed (Avula et al., 2011) . The same study reported that intestinal schistosomiasis and trinitrobenzene sulfonic acidinduced ileitis resulted in decreased expression of both receptors, whereas other neuronal marker proteins, e.g., calretinin or neuronal nitric oxide synthetase (nNOS), were not affected by either inflammatory insult. MRGPRH transcripts were also detectable in the heart (Wittenberger et al., 2001) , and expression of human MRGPRX2 was described in the adrenal glands and in several brain areas (Robas et al., 2003; Kamohara et al., 2005) .
D. Evolution
The MRGPR subfamilies D to G constitute evolutionarily old genes that are conserved between rodents and primates. Accordingly, although all MRGPR are encoded on only one chromosome in each species analyzed, the subfamilies D to G lie clustered together a considerable distance apart from the chromosomal region encoding subfamilies A to C in rodents or subfamily X in primates (Zylka et al., 2003) . The phylogenetic relationship between the latter MRGPR subfamilies poses the question of how and why the entire MRGPR family developed in such a complex MAS-Related G Protein-Coupled Receptors manner during mammalian evolution. A current model (see Fig. 2 ) rests on the assumption that an ancestral progenitor gene cluster of one MRGPRA/C/X gene and one MRGPRB gene existed before rodent speciation (Zylka et al., 2003 ). An unequal crossing over event led to local MRGPRB gene duplication in the rodent lineage, whereas MRGRPB genes were completely lost in the primate lineage. In rodents, the MRGPRA/C/X progenitor developed into two separate gene subfamilies because of a further round of local gene duplication. Specifically in mice, the de novo insertion of the L1 retrotransposon initiated several additional local gene duplication events of MRGPRA and -C genes. However, additional MRGPRC genes lost their transcriptional regulatory elements and are now pseudogenes. This assumption is supported by the observation that all MRGPR genes are found on only one chromosome, e.g., chromosome 1q in rats or chromosome 7B in mice. Notably, such an evolutionary model would also explain the highly specific expression of rodent MRGPRA and -C and of human MRGPRX in primary sensory neurons, assuming that those promoter elements crucial for the restrictive expression pattern already existed in the progenitor gene and were preserved during gene duplication events (Dong et al., 2001; Lembo et al., 2002; Zylka et al., 2003; Zhang et al., 2005) . Likewise, additional expression of MRGPRX1 and -2 in human mast cells could be the result of conserved ancestral promoter elements responsible for MRGPRB expression in rat mast cells (Tatemoto et al., 2006) . Thus, MRGPRX1 and -2 inherited their restrictive expression in primary sensory neurons and mast cells by a combination of gene expression regulatory elements of rodent MRGPRA/C and certain rodent MRGPRB genes.
The development of single MRGPRX genes in primate evolution was also initiated by local gene duplication (note that all human MRGPRX genes are Fig. 2 . Schematic model displaying the putative divergent evolution of the MRGPRA/B/C/X gene cluster in primates and rodents. Based on the data provided by Zylka et al. (2003) , a theoretical model explaining the evolutionary events leading form a putative ancestral MRGPR gene cluster to the primate and rodent lineage and further on to species-specific distinctions in the rodent lineage is given. located on chromosome 11p15.1) (Dong et al., 2001; Choi and Lahn, 2003; Zylka et al., 2003) . Diversion of distinct MRGPRX genes was driven by significant positive selection pressure (Choi and Lahn, 2003; Fatakia et al., 2011) , resulting in amino acid substitutions in those parts of transmembrane domains forming the ligand binding cavity, in extracellular domains, and in the very C-terminal tail (Choi and Lahn, 2003; Fatakia et al., 2011) . From a structural point of view, the latter changes may have resulted in diverging receptor proteins with regard to ligand specificity or affinity (extracellular domains, transmembrane domains) and the regulation of signaling (C-terminal tail). From an evolutionary point of view, the strong positive selection pressure indicates that novel MRGPRX proteins are crucial for primatespecific physiology and represent important differences between primates and rodents. Indeed, primate-specific genes are clearly over represented in the fraction of human disease-causing genes (Hao et al., 2010) . Interestingly, a continuing positive selection pressure on MRGPRX genes may account for frequent polymorphisms of MRGPRX genes in the human population and, thus, account for differences in published MRGPRX/SNSR subtypes.
III. Pharmacology and Physiology of MAS-Related G Protein-Coupled Receptors
A. Preface
To date, no MRGPR subtype has officially been declared "deorphanized" by NC-IUPHAR (Davenport et al., 2013) . This recommendation would require at least two independent demonstrations of receptorligand pairing published in refereed papers. To "deorphanize" a receptor, NC-IUPHAR suggests using radioligand binding and functional assays in in vitro systems and native tissues in conjunction with anatomic data indicating that the proposed ligand is present to activate the receptor in a given tissue. Additionally, genetic approaches that alter expression levels of the receptor or the ligand might be beneficial. So far, at least one of the criteria mentioned is lacking for any given MRGPR. These criteria are particularly hard to meet for human MRGPRX subtypes: because of their specific expression in primates and their restricted expression pattern in primary sensory neurons and mast cells, it appears difficult to obtain data from native tissues and to implement genetic approaches that would alter protein expression levels. However, knowledge of MRGPR biology and pharmacology is expanding, a fact that is being appreciated by NC-IUPHAR (Davenport et al., 2013) . Interestingly, a certain degree of pharmacologic overlap of nonorthologous MRGPR members exists, although MRGPR phylogeny is complex, including subfamilies that are specific to rodents and others that are primate specific. Thus, we will summarize the available pharmacologic data of MRGPR members ordered by subfamily and review the current knowledge about signaling cascades and physiologic effects elicited by a given receptor-ligand pair.
B. MAS-Related G Protein-Coupled Receptors A 1. Pharmacology. Endogenous or exogenous ligands have been assigned to only 4 of 19 MRGPRA members, i.e., rat MRGPRA and three murine MRGPRA (see Table 3 ). The murine MRGPRA members 1 and 4 were the first MRGPR to be analyzed in a functional assay. After recombinant expression in human embryonic kidney (HEK)293 cells, both receptors responded to several peptides of the RFamide family (Dong et al., 2001 ) first discovered in mollusks and soon shown to modulate nociception in vertebrates (Price and Greenberg, 1977; Yang et al., 1985) . The mammalian neuropeptide FF (NPFF) increased intracellular calcium concentrations via MRGPRA1 with a potency of ;200 nM, whereas the mammalian neuropeptide AF (NPAF) likewise activated the MRGPRA4 subtype with a potency of ;60 nM. These findings were subsequently confirmed by others (Han et al., 2002; Liu et al., 2009 ). Both peptides are also known to activate NPFF receptor 1 or 2 with potencies and affinities in the nanomolar range (Mollereau et al., 2002) . Thus, if these neuropeptides represent the endogenous agonists of murine MRGPRA1 or -4, they would not be selective for the latter receptors. In addition to endogenously occurring neuropeptides, murine MRGPRA1 was found to be a target of the human version of the b-salusin peptide, employing fluorescence imaging plate reader technology and MRGPRA1 overexpressing HEK293 or Chinese hamster ovary (CHO) cells (Wang et al., 2006b) . As the orthologous murine peptide failed to activate MRGPRA1, it was concluded that b-salusin is only a surrogate ligand of MRGPRA1.
The antimalaria drug chloroquine was recently shown to induce intracellular calcium transients in cells expressing MRGPRA3 (Liu et al., 2009 ). This response was characterized by an EC 50 value of ;27 mM after heterologous expression in HEK293 cells and was also noted in dissociated primary sensory neurons. A cluster knockout mouse deficient of several MRGPR (including MRGPRA1-4, -A10, -A12, -A14, -A16, -A19, -B4, -B5, and -C) failed to respond to chloroquine as did wild-type neurons after small interfering RNAmediated MRGPRA3 knockdown, indicating that MRGPRA3 are indeed targeted by chloroquine (Liu et al., 2009) . Notably, chloroquine also induced calcium signals after recombinant expression of rat MRGPRA in primary sensory neurons derived from the MRGPR cluster knockout mouse (Liu et al., 2009) .
The purine adenine might serve as an endogenous agonist of rat MRGPRA, because in silico modeling revealed a putative adenine binding pocket in the rat MRGPRA protein (Heo et al., 2007b) . This assumption was corroborated by the observation that adenine bound to rat MRGPRA with a K D value of 24 nM, when the receptor was overexpressed in CHO cells (Bender et al., 2002) . In this cellular model, adenine inhibited forskolin-induced adenylyl cyclase activity and induced guanosine 59-O-(3-[
35 S]thio)triphosphate binding to the plasma membrane with potencies of ;3 and ;60 nM, respectively. However, inhibition of cAMP production by rat MRGPRA points to G i/o and not to G q/11 as downstream effectors in CHO cells. This observation contrasts with the functional properties of murine MRGPRA1 that was found to exclusively engage classic G q/11 signaling cascades (Han et al., 2002; Wang et al., 2006b) .
2. Signaling Cascades and Physiologic Effects. Physiologic effects and detailed signaling cascades of MRGPRA members have so far been described for the murine chloroquine-sensitive subfamily member MRGPRA3 (see Fig. 3 ). Intradermal application of chloroquine induced a profound itching behavior at the injection site (Liu et al., 2009 ). This procedure did not lead to alloknesis, an aberrant sensation of itch when nonitching skin near an itchy skin patch is lightly touched (Akiyama et al., 2012) . Chloroquine-induced calcium signals in primary sensory neurons were completely inhibited by removal of extracellular calcium by EGTA and by ;90% after application of ruthenium red, a blocker of transient receptor potential (TRP) cation channels (Liu et al., 2009) . By use of calcium imaging of cultured primary sensory neurons and MRGPRA3 transfected NG108 cells, intracellular signaling cascades were analyzed that might be responsible for the sensation of itch (Wilson et al., 2011) . Most interestingly, chloroquine induced an increase in intracellular calcium through TRP ankyrin 1 (TRPA1) channels, because chloroquine-induced itching was not observed in TRPA1-deficient mice (Wilson et al., 2011) . The TRP vanilloid 1 (TRPV1) channel, an established sensor of different painful stimuli such as heat and protons (Caterina et al., 1997) , is also expressed in chloroquine-responsive neurons (Liu et al., 2009; Wilson et al., 2011) . In contrast to TRPA1, TRPV1 is not required for MRGPRA3-dependent neuronal excitation, and chloroquine-induced calcium signals were not detected in cells coexpressing MRGPRA3 and TRPV1 (Wilson et al., 2011) . Functional coupling between MRGPRA3 and TRPA1 was assigned to Gbg protein complexes because of the lack of calcium signals after incubation with the Gbg inhibitor gallein. The authors further showed that functional interactions between TRPA1 and MRGPRA3 are required for the physiologic effects of the latter. Than and coworkers (2013) confirmed that direct activation of MRGPRA3 by chloroquine excites murine primary sensory neurons because of TRPA1 activation, because the response of these neurons was abolished by the TRPA1 inhibitor HC-030031 [1,2,3,6-tetrahydro-1,3-dimethyl-N-[4-(1-methylethyl)phenyl]-2,6-dioxo-7H-purine-7-acetamide, 2-(1,3-dimethyl-2,6-dioxo-1,2,3, 6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl) acetamide]. However, the authors revealed that MRGPRA3 was also able to induce calcium signals in TRPA1-negative neurons. By use of YM58483 (N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide) as a nonsubtype selective canonical TRP and Pyr3 as a TRPC3 blocker, TRPCs and, in particular, the TRPC3 subtype were identified as the downstream effectors mediating MRGPRA3-induced neuronal excitation in the absence of TRPA1 (Than et al., 2013) . In addition, this work showed profound sensitization of TRPV1 channels via chloroquine-induced protein kinase C (PKC) activation and inhibition of the cold sensor TRP melastatin 8 (TRPM8) via direct binding of the Ga q subunit to the ion channel, because a Ga q chimera unable to activate phospholipase C (PLC)b still blocked TRPM8 activity in cells lacking functional Ga q proteins (McKemy et al., 2002; Peier et al., 2002) . Thus, although acute signaling of MRGPRA3 via TRPA1 solely leads to itch (Liu et al., 2009; Wilson et al., 2011) , chloroquine also activates cellular signaling cascades that might affect other physiologic processes, such as nociception or temperature sensation.
C. MAS-Related G Protein-Coupled Receptors B
None of the rodent MRGPRB members has been assigned to any ligand so far. However, in a reporter mouse that carries a gene for placental alkaline phosphatase under the control of the MRGPRB4 promoter, a rare subset of primary sensory neurons that only innervates the hairy skin showed high promoter activity (Liu et al., 2007) . These neurons were nonpeptidergic, TRPV1 negative, displayed a broad arborization of their cutaneous termini, and are often associated with hair follicles. Most interestingly, MRGPRB4 positive neurons project to the spinal lamina II o , a spinal pain processing center that is part of the substantia gelatinosa (Rexed, 1952) . These findings suggested that MRGPRB4 mark C-fiber tactile afferents that are supposed to detect gentle touch and stroking. Indeed, activation of MRGPRB4-positive primary sensory neurons, but not activation of the MRGPRB4 itself, by gentle stroking was demonstrated by an elegant in vivo calcium imaging approach. Pharmacogenetic activation of MRGPRB4 expressing neurons in freely moving mice resulted in conditioned place preference, suggesting that activation of these neurons is positively reinforcing and might be induced by interindividual social interactions such as allogrooming (Vrontou et al., 2013) .
D. MAS-Related G Protein-Coupled Receptors C 1. Pharmacology. The rodent MRGPRC subfamily consists of only one protein-encoding gene in rats and mice, and both receptor subtypes have been suggested to bind several ligands (see Table 4 ). After heterologous expression in different cell systems, MRGPRC from rat and mouse were activated to elicit calcium signals by a set of different but structurally related peptides (see Fig. 4A ) with potencies in the low to medium nanomolar range (Grazzini et al., 2004; Han et al., 2005; Fig. 3 . Schematic presentation of signaling cascades, downstream targets, and physiologic effects proposed for murine MRGPRA3. Upon chloroquineinduced activation of MRGPRA3 in primary sensory DRG/trigeminal ganglia neurons, the activity of several TRP channels is modulated via distinct mechanisms. TRPC3 is activated via an unknown mechanism, TRPA1 activation is mediated by Gbg subunits, TRPV1 is sensitized via PKC-mediated phosphorylation, and TRPM8 is inhibited via Ga q signaling independently from PLCb activation. MRGPRA3-mediated TRPA1 activation leads to itch, whereas physiologic effects of TRPA1-independent signaling cascades have not yet been determined. Used with permission.
MAS-Related G Protein-Coupled Receptors Heo et al., 2007a; Solinski et al., 2010 Solinski et al., , 2013 . Among these peptides are g 2 -melanocyte stimulating hormone (g 2 -MSH), BAM peptides, dynorphin-14, and proneuropeptide-FF-A peptides. Notably, these peptides originate from PENK (BAM), pro-opiomelanocortin (g 2 -MSH), prodynorphin (dynorphin-14), and NPPFA (NPFF or NPAF) (see Fig. 4A ). Such a wide range in the binding profile of a distinct GPCR is quite unique and suggests that many different physiologic pathways rely on MRGPRC signaling. Activation of MRGPRC by BAM peptides was validated in primary sensory neurons of mice (Liu et al., 2009; Wilson et al., 2011) and rats (Honan and McNaughton, 2007) . However, their similarities notwithstanding, several pharmacological differences between murine and rat MRGPRC have also been observed (see Fig. 4B ): NPFF peptides displayed lower potency to activate the rat MRGPRC compared with the murine counterpart, and dynorphin-14 did not activate rat MRGPRC at all (Han et al., 2002; Grazzini et al., 2004; Solinski et al., 2013) . Regarding efficacy, g 2 -MSH and BAM peptides are the most efficacious activators of both MRGPRC, with g 2 -MSH clearly surmounting BAM peptides (Solinski et al., 2013) . Using in silico modeling and site-directed mutagenesis, Heo and coworkers (2007a) Several peptides that are now recognized as MRGPRC agonists were previously shown to activate distinct receptors from other GPCR families, e.g., g 2 -MSH also binds to melanocortin 3 receptors and some BAM peptides to opioid receptors (OR). Interestingly, ligand sharing with receptor subtypes of other GPCR families is not restricted to MRGPRC, but appears to be a common feature of many MRGPR as summarized in Table 9 (Bowery et al., 1980; Quirion and Weiss, 1983; Roselli-Rehfuss et al., 1993; de Lecea et al., 1996; Fukusumi et al., 1997; Kaupmann et al., 1997; Oosterom et al., 1999; Han et al., 2002; Lembo et al., 2002; Mollereau et al., 2002; Robas et al., 2003; Santos et al., 2003; Grazzini et al., 2004; Shinohara et al., 2004; Gembardt et al., 2008; Lautner et al., 2013) . Although, ligand sharing between MRGPRC and other GPCR subtypes is of physiologic interest, it is also a major concern when considering the specificity of distinct MRGPRC-activating peptides in vivo. Interestingly, after N-terminal truncation of g 2 -MSH (g 2 -MSH6-12) or of BAM1-22 (BAM8-22) activity toward MRGPRC but not toward melanocortin 3 receptor or OR is preserved (Lembo et al., 2002; Grazzini et al., 2004) . Accordingly, g 2 -MSH6-12 or BAM8-22 are regarded as specific MRGPRC ligands and can be used in in vivo studies to analyze the physiologic effects of MRGPRC in mice or rats. When considering g 2 -MSH or BAM derivatives as putative endogenous MRGPRC ligands, it is also important to investigate whether these peptides are actually released from precursors under physiologic or pathophysiological conditions. g 2 -MSH and BAM1-22 have both been shown to be present in several tissues, including spinal cord and brain (Mizuno et al., 1980; Pelletier et al., 1981; Hollt et al., 1982; DeBold et al., 1988a,b; Cai et al., 2007a) . Thus, peptides that bind other GPCRs and MRGPRC could serve as endogenous ligands of the latter. The specific MRGPRC agonist BAM8-22 was also identified in vivo after microdialysis of exogenous BAM1-25 580 into the striatum of anesthetized rats, using a combination of solid-phase preconcentration capillary electrophoresis and imaging matrix-assisted laser desorption/ ionization mass spectrometry (Zhang et al., 1999) . However, although the proteolytic machinery to generate BAM8-22 in vivo is present in the brain, it has not yet been shown that BAM8-22 or g 2 -MSH6-12 are produced endogenously in tissues adjacent to primary sensory neurons. Thus, it remains unclear whether and under which circumstances specific MRGPRC ligands exist in vivo. Very recently, it was proposed that the "SLIGRL"-peptide activates murine MRGPRC . "SLIGRL" is not a classic neuropeptide released from common precursor proteins but part of the tethered ligand domain of murine protease-activated receptors 2 (PAR2) [for further reading see these comprehensive reviews (Steinhoff et al., 2005; Ramachandran and Hollenberg, 2008) ]. PAR are GPCR that are activated by serine proteases such as thrombin or trypsin. To activate PAR, proteases cleave N-terminal peptides from the PAR protein, thereby exposing a "cryptic" PAR-activating sequence at the N terminus. Short peptides that are derived from theses cryptic sequences have also been shown to activate PAR without previous cleavage, e.g., the "SLIGRL"-amide was established as a PAR2-specific ligand. However, it may also be possible that peptides such as the "SLIGRL"-peptide are released from PAR through consecutive cleavage by two or more proteases and in turn serve as ligand of distinct GPCR. By use of CHO cells recombinantly expressing MRGPRC, small interfering RNAmediated MRGPRC knockdown in wild-type primary sensory neurons, and primary sensory neurons from MRGPRC-deficient mice, "SLIGRL"-induced calcium signals in the presence, but not in the absence of the MRGPRC were identified, indicating that the "SLIGRL"-peptide is indeed a ligand of this receptor. Analysis of structure-activity relationships revealed that amidation of the "SLIGRL" C terminus is important for its function as a ligand, which fits well to the proposed RF(Y)G/amide consensus sequence of other MRGPRC agonists. Notably, "SLIGRL"-induced itch, which was believed to be mediated by PAR2 (Shimada et al., 2006) , was not changed in PAR2-deficient mice . In MRGPRC overexpressing CHO cells, a high EC 50 value of ;10 mM for "SLIGRL"-induced calcium signals was measured . However, because PAR2 and MRGPRC are both expressed in primary sensory neurons, it is appealing to speculate that the "SLIGRL" peptide might physiologically exist in concentrations high enough to stimulate MRGPRC.
2. Signaling Cascades and Physiologic Effects. a. Preface. Rat and murine MRGPRC elicit their effects primarily by the activation of G proteins. Both receptors were shown to induce intracellular calcium release via activation of PLCb (Han et al., 2002; Grazzini et al., 2004) . For murine MRGPRC coupling to G q/11 proteins seems to be essential, because MRGPRC-dependent calcium signaling was absent in murine embryonic fibroblasts derived from G q/11 -deficient embryos (Han et al., 2002) . In accordance with their selective expression in small-diameter primary sensory neurons, MRGPRC signaling in mice and rats has been implicated in somatosensory detector functions in the skin. Indeed, published data on the in vivo effects of MRGPRC agonists detected painenhancing, pruritogenic, but also analgesic effects (summarized in Fig. 5) .
b. Pain-enhancing effects. Intraplantar injections of the MRGPRC-specific peptides BAM8-22 or Tyr 6 -g 2 -MSH6-12 into juvenile or adult rats dose dependently resulted in acute nocifensive behavior, thermal hyperalgesia, and mechanical allodynia (Grazzini et al., 2004; Ndong et al., 2009) . Likewise, intrathecal injection of MRGPRC agonists into juvenile or adult rats and Kunming mice also induced acute pain-like behavior and thermal hyperalgesia (Grazzini et al., 2004; Chang et al., 2009; Wei et al., 2010) . MRGPRC may also be responsible for inflammatory pain, because complete Freund's adjuvant (CFA)-induced thermal hyperalgesia was alleviated by RNAi-mediated MRGPRC knockdown in rats (Ndong et al., 2009 ). (Han et al., 2002; Lembo et al., 2002; Grazzini et al., 2004; Liu et al., 2009 Liu et al., , 2011 Solinski et al., 2013) . For simplicity, ligands that exhibit potencies more than 10 times lower than g 2 -MSH (in the case of MRGPRC) or BAM8-22 (in the case of MRGPRX1) are not shown.
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Notably, pain-enhancing effects of MRGPRC can only be assessed at low agonist doses (e.g., up to 20 nmol of Tyr 6 -g 2 -MSH6-12) and in a rigid time window of a maximum of 20 minutes postinjection (Wei et al., 2010) . This low dose effect may be due to the activation of an analgesic off-target at higher peptide concentrations, most likely the Kyotorphin receptor, which masked MRGPRCinduced pain, whereas rapid peptide degradation may be responsible for the short-term response (Grazzini et al., 2004; Wei et al., 2010) .
Several publications identified heat-sensitive TRPV1 ion channels as major downstream targets of MRGPRC responsible for its pain-enhancing effects (Honan and McNaughton, 2007; Hager et al., 2008; Ndong et al., 2009; Wilson et al., 2011) . In rat primary sensory neurons, BAM8-22 sensitized TRPV1 for its agonist capsaicin (CAP) via a PKC-dependent pathway (Honan and McNaughton, 2007) . The PKC isoforms d, «, and z were excluded to be part of this signaling cascade, because these isoforms did not translocate to the plasma membrane after MRGPRC stimulation. TRPV1 sensitization was also made responsible for an increased CAP-or heat-induced calcitonin gene-related peptide (CGRP) release from rat or mouse paw skin after preincubation with BAM1-22 in conjunction with naloxone, an opioid receptor antagonist that blocks effects of BAM1-22 on opioid receptors but still allows BAM1-22 to act on MRGPRC (Hager et al., 2008) . Itch is caused via PLCb-mediated activation of TRPA1. Acute pain, thermal hyperalgesia, and mechanical allodynia were found to depend on PKCmediated TRPV1 sensitization, peripheral CGRP release, and spinal nitric oxide (NO) production and NMDA receptor activity. Different pain-inducing paradigms (marked with red bolts) lead to acute nociceptor activity as well as adaptive changes including CGRP induction, spinal NO production, and windup of spinal dorsal horn neurons. These changes are occasionally accompanied by MRGPRC induction and increased abundance of BAM1-22 that can lead to enhanced MRGPRC signaling. Analgesic effects of MRGPRC are partly triggered by engagement of MOP signaling that counteracts adaptive changes in DRG and spinal neurons. Chronic application of morphine leads to tolerance, among others via induction of similar adaptive changes as in pain paradigms. Rat MRGPRC have been shown to counteract these processes.
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Interestingly, BAM8-22 or g 2 -MSH alone failed to induce CGRP release, and, surprisingly, a combination of BAM1-22 and naloxone that sensitized TRPV1 for CAP still induced CGRP release from skin preparations derived from TRPV1-deficient mice. In rats, MRGPRC-mediated thermal hyperalgesia was abrogated by a specific TRPV1 inhibitor (Ndong et al., 2009) , and coexpression of TRPV1 with murine MRGPRC in NG108 cells resulted in augmented calcium signals by BAM8-22 (Wilson et al., 2011) . Thus, TRPV1 has been defined as a common target for cellular signaling induced by MRGPRC, which might be of high physiologic significance because coexpression of TRPV1 with MRGPRC in rodent primary sensory neurons was frequently observed (Lembo et al., 2002; Hager et al., 2008; Liu et al., 2009 ).
In addition to TRPV1, Chang and coworkers (2009) (Chang et al., 2009) . Because nNOS inhibitors also diminished NMDA-induced pain-like behavior (Kitto et al., 1992) , it remained unclear whether both players are directly modulated by MRGPRC in the same cell.
c. Analgesic effects. In contrast to painenhancing effects of MRGPRC, several studies have established analgesic effects of MRGPRC-specific agonists Zeng et al., 2004; Chen et al., 2006 Chen et al., , 2008 Chen et al., , 2012 Cai et al., 2007a; Guan et al., 2010; Jiang et al., 2013) . Acute nocifensive behavior after formalin or NMDA injection was found to be diminished dose-dependently by BAM1-22 plus naloxone and by BAM8-22 or Tyr 6 -g 2 -MSH6-12 applied alone Zeng et al., 2004; Chen et al., 2006 Chen et al., , 2008 . In parallel, spinal c-Fos immune reactivity, an established marker of nociception (Bullitt, 1989) , was reduced by MRGPRC agonists. Thermal hyperalgesia after intraplantar formalin or CFA injection, quantified either by tail flick or Hargreaves's tests, were found to be diminished by MRGPRC agonists Guan et al., 2010; Jiang et al., 2013) . Interestingly, CFA-induced thermal hyperalgesia was augmented in the MRGPR cluster knockout mice (see section III.B.1) that are deficient for MRGPRC (Guan et al., 2010) . Mechanical hyperalgesia, a hallmark of CFA-induced inflammatory and spinal nerve ligation-or chronic constriction injury-induced neuropathic pain, was also reduced by application of MRGPRC agonists (Cai et al., 2007a; Guan et al., 2010; Chen et al., 2012; Jiang et al., 2013) . MRGPRC upregulation and increased abundance of its agonist BAM1-22 have been observed during the process of CFA-induced pain chronification (Cai et al., 2007a; Jiang et al., 2013) . Consequently, acute intrathecal application of a BAM1-22-neutralizing antibody decreased CFAinduced mechanical hyperalgesia, thus highlighting ongoing MRGPRC signaling during inflammatory pain (Cai et al., 2007a) . After CFA injection, enhanced MRGPRC signaling inhibited the induction of CGRP in primary sensory and of nNOS in spinal projection neurons (Jiang et al., 2013) , which is believed to exert long lasting effects on spinal sensitization [for details see (Latremoliere and Woolf, 2009) ]. This was attributed to the engagement of m-OR (MOP), as evidenced by the lack of inhibition after preincubation with the MOP inhibitor CTAP.
d. Pruritogenic effects. Concomitant to the observation that chloroquine-induced scratching behavior is mediated largely by murine MRGPRA3 signaling, intradermal injections of BAM8-22 into the nape of the neck of mice also elicited a profound scratching behavior (Liu et al., 2009 ). This behavioral result was confirmed by several other studies, the proposed murine MRGPRC agonist "SLIGRL" also elicited itch, and agonist-induced scratching was diminished to ;25% in the MRGPR cluster knockout mouse (see section III.B.1) that lacks MRGPRC (Liu et al., 2009 Wilson et al., 2011; Akiyama et al., 2012; Han et al., 2013) . However, intradermal injections into the nape of the neck as a secure test for itch were questioned because pain-inducing algogens and pruritogens elicit nearly indistinguishable reactions after this application procedure (Shimada and LaMotte, 2008) . Instead the "cheek model of itch" was proposed, which is based on intradermal cheek injections and enables discrimination of itch and pain. Cheek injections of pain-inducing algogens are followed by intense wiping, whereas pruritogens elicit a vigorous scratching response. Therefore it is important to note that BAM8-22 injected into the cheek of mice elicited only scratching without any wiping reaction (Wilson et al., 2011) . The notion that murine MRGPRC cause itch without pain is further accompanied by the finding that ablation of MRGPRA3-positive primary sensory neurons that almost all express MRGPRC (Zylka et al., 2003; Liu et al., 2009 ) completely abolished BAM8-22-or "SLIGRL"-induced scratching (Han et al., 2013) . The latter study is of particular interest because it showed that MRGPRA3/MRGPRC-positive neurons are involved in itch, but not pain perception in mice. Noteworthy, activation of MRGPRC by BAM8-22, but not by "SLIGRL" induced alloknesis in addition to acute itch, which were both independent of histamine signaling (Akiyama et al., 2012) . Wilson and coworkers (2011) analyzed downstream effectors involved in MRGPRC-induced itching. Although the percentage of primary sensory neurons that MAS-Related G Protein-Coupled Receptors 583 elicited BAM8-22-induced calcium signals was diminished in TRPV1-deficient cells, action potentials after BAM8-22 application were not altered. In contrast, TRPA1 deficiency resulted in the reduction of both responses, calcium signals and action potentials. Accordingly, BAM8-22-induced scratching responses were absent only in TRPA1-deficient mice, whereas TRPV1 deficiency was dispensable.
E. MAS-Related G Protein-Coupled Receptors D 1. Pharmacology. The MRGPRD subfamily consists of only one receptor subtype per species, which is conserved in rodents and primates, and several ligands have been implicated in MRGPRD pharmacology (see Table 5 ). b-[ 3 H]Alanine is able to bind to the human MRGPRD after heterologous expression in CHO cells (Shinohara et al., 2004) . Measuring calcium signals in these cells, an EC 50 value of ;15 mM was determined that is three to 4-fold below b-alanine concentrations observed in rat sciatic nerve or cat brain samples (Tallan et al., 1954; Marks et al., 1970) . In line with this observation for human MRGPRD, rat or mouse MRGPRD also responded to b-alanine after heterologous expression in CHO cells with calcium signals and EC 50 values between 3 and 44 mM (Shinohara et al., 2004; Zhang et al., 2007; Ajit et al., 2010) . b-Alanine induced signaling in MRGPRD-enriched fractions of primary sensory neurons from rat (Crozier et al., 2007) and calcium signals or action potentials in murine primary sensory neurons . Thus, b-alanine has been established as a ligand of MRGPRD and could be responsible for their endogenous effects. Interestingly, two other amino acids, GABA and b-aminoisobutyric acid, have also been shown to induce calcium signals via human MRGPRD, although with lower potency compared with b-alanine (Shinohara et al., 2004; Ajit et al., 2010; Uno et al., 2012) . However, because b-alanine and GABA also bind to other proteins, including GPCR and ion channels (Bowery, 1993; Macdonald and Olsen, 1994; Tiedje et al., 2010) , in vivo effects of both amino acids would have to be interpreted with caution regarding the molecular receptor entity.
In addition to amino acids, two peptides produced by the renin-angiotensin system have also been identified as MRGPRD ligands. Precisely, angiotensin-(1-7) and alamandine [Ala 1 -angiotensin-(1-7)] were proposed to activate MRGPRD (Gembardt et al., 2008; Lautner et al., 2013) . Angiotensin-(1-7) is also established to bind the MAS1 receptor in vivo (Santos et al., 2003) and is therefore not specific for MRGPRD. Further screening approaches revealed novel exogenous compounds that specifically activate or inhibit MRGPRD activity (Zhang et al., 2007; Ajit et al., 2010; Uno et al., 2012) . These specific ligands will be very useful tools for the analysis of the in vivo effects of MRGPRD in the future.
2. Signaling Cascades and Physiologic Effects. Several cellular studies agree that MRGPRD couple to G q/11 and pertussis toxin (PTX)-sensitive G i/o proteins, because MRGPRD induced PTX-insensitive calcium releases and PTX-sensitive inhibition of forskolininduced adenylyl cyclase activation (Shinohara et al., 2004; Ajit et al., 2010) . G i/o coupling links MRGPRD to KCNQ2/3 channels, and inhibition of KCNQ2/3 activity is mainly responsible for the inhibition of noninactivating potassium currents (M-currents) induced by MRGPRD in (Crozier et al., 2007) . This signaling cascade was implicated to contribute to MRGPRD-dependent enhanced neuronal activity (Crozier et al., 2007) . Likewise, decreased neuronal activity was detected in MRGPRD-deficient mice (Rau et al., 2009) .
Just like other MRGPR members, MRGPRD also specifically mark a discrete subset of primary sensory neurons. Genetically engineered axonal tracers map the stratum granulosum of the skin as the only peripheral target of MRGPRD-positive neurons (Zylka et al., 2005) . MRGPRD neurons form synapses in the spinal lamina II (Zylka et al., 2005) and convey their signal monosynaptically to almost all known classes of spinal lamina II neurons, as evidenced by an optogenetical circuit mapping approach . MRGPRD-positive neurons were classified as nonpeptidergic C-fiber nociceptors that coexpress the ionotropic ATP receptor P2X3, tetrodotoxin-insensitive Na V channels, MOP, and partly the TRPV1 ion channel (Shinohara et al., 2004; Zhang et al., 2005; Zylka et al., 2005; Dussor et al., 2008) . The functional analysis of these cells for sensory transduction revealed a complex picture. MRGPRD-deficient mice exhibit deficits in the detection of mechanical, heat, and cold stimuli, whereas ablation of MRGPRD-positive neurons only impacted acute mechanical pain and mechanical hyperalgesia in a CFA model of inflammatory pain, whereas heat and cold transduction was completely preserved (Cavanaugh et al., 2009; Rau et al., 2009 ). In accordance with the latter finding, ablation of MRGPRD-positive primary sensory neurons reduced the firing rate and abundance of spinal dorsal horn neurons responding to mechanical but not heat stimuli . Finally, stimulation of MRGPRDpositive neurons with b-alanine only induced calcium signals and action potentials in ;40% of genetically labeled MRGPRD-expressing cells . This response elicited itch in mice, because itch was completely abrogated by MRGPRD deficiency. In vivo electrophysiological recordings revealed that b-alanineactivated neurons are heat-and mechanosensitive, whereas the remaining heat-insensitive subset of MRGRPD neurons that did not respond to b-alanine was solely mechanosensitive. Thus, the latter population might be responsible for deficits in mechanical pain that was observed after ablation of MRGPRDpositive neurons (Cavanaugh et al., 2009) . Interestingly, intradermal application of b-alanine during a pilot human study that comprised 11 individuals also resulted in itch, pricking/stinging, and burning , indicating that MRGPRD similarly affect itching in humans and rodents.
Transcripts of MRGPRD were also detected in other tissues than in primary sensory neurons, including arteries (Shinohara et al., 2004) . Moreover, the angiotensinogen cleavage product alamandine circulates in human blood and produces physiologic effects that resemble those produced by angiotensin-(1-7), including relaxation of aortic rings. These actions of alamandine were not mediated via MAS1 or angiotensin II type 2 receptors (AT 2 R) but required MRGPRD activation (Lautner et al., 2013) . Surprisingly, the abovementioned MRGPRD agonist b-alanine did not relax aortic rings, but blocked the effects of alamandine, suggesting that both MRGPRD agonists direct MRGPRD-induced signaling to different pathways. Effects of MRGPRD in primary sensory neurons and the vasculature are summarized in Fig. 6 .
F. MAS-Related G Protein-Coupled Receptors E to -H
The subfamilies MRGPRE to -H consist of only one receptor per species and are conserved in rodents and primates, except for MRGPRH that only exists in rodents. So far, no member of these MRGPR has ever been assigned to any ligand, which severely hampered their functional characterization. A MRGPRE-deficient mouse strain, which exhibited normal acute pain responses in a hot plate assay but showed a trend toward decreased nocifensive behavior in both phases of the formalin test as well as statistical significant deficits in the induction, but not maintenance, of mechanical allodynia after chronic constriction injury, was also established (Cox et al., 2008) .
a. MAS-related G protein-coupled receptors X1. The human MRGPRX1 was the first primate-specific MRGPR to be assigned to a ligand, and several additional agonistic and antagonistic compounds have been identified thereafter (see Table 6 ). MRGPRX1 have been shown to bind BAM peptides with high affinity (K D value of BAM8-22 ;10 nM) after expression in HEK293 cells (Lembo et al., 2002) . Likewise, BAM peptides elicited intracellular calcium release in the same cells (Lembo et al., 2002) . In accord with rodent MRGPRC, agonistic activity of BAM peptides was completely preserved in an N-terminal truncated form of . EC 50 values of either BAM8-22 or BAM1-22 and MRGPRX1 in calcium assays varied between ;14 and ;800 nM (Lembo et al., 2002; Burstein et al., 2006; Tatemoto et al., 2006; Shemesh et al., 2008; Malik et al., 2009; Solinski et al., 2013) .
Despite sharing BAM peptides as agonists, human MRGPRX1 and rodent MRGPRC also displayed pharmacological differences (see Fig. 4B ). For instance, proneuropeptide-FF-A cleavage products or dynorphin-14, which are partial agonists of MRGPRC, did not activate MRGPRX1 at all, and importantly, g 2 -MSH, the most potent and efficacious agonist of rodent MRGPRC, only faintly activated MRGPRX1 when chimeric G proteins were coexpressed (Lembo et al., MAS-Related G Protein-Coupled Receptors 2002; Solinski et al., 2013) . Moreover, cyclic dimers of the C-terminal part of g 2 -MSH were introduced to antagonize BAM8-22-induced MRGPRX1 activation, but do not bind rodent MRGPRC (Schmidt et al., 2009) . Therefore, the common RF(Y)G/amide consensus of MRGPRC agonists does not apply to MRGPRX1. As a consequence MRGPRC exhibit a high promiscuity toward many ligands, whereas MRGPRX1 are much more restrictive and solely bind BAM peptides, a feature conserved to a certain degree in the MRGPRX1 of rhesus monkeys (Burstein et al., 2006) .
In addition to potential endogenous agonists, exogenous agonists of MRGPRX1, e.g., tetracyclic benzimidazoles, have been proposed (Malik et al., 2009 ). Furthermore, 2,4-diaminopyrimidine derivates and 2,3-disubstituted azabicyclooctanes antagonize BAM8-22-induced signaling via MRGPRX1 (Kunapuli et al., 2006; Bayrakdarian et al., 2011) . Interestingly, the MRGPRA3 ligand chloroquine also activated MRGPRX1, although affinity was 1000-fold and efficacy ;2.5-fold reduced compared with BAM8-22 (Liu et al., 2009) . Hence, in accordance with its evolutionary relation Fig. 6 . Schematic presentation of signaling cascades, downstream targets, and physiologic effects proposed for MRGPRD in primary sensory DRG/ trigeminal ganglia (TG) neurons and blood vessels. b-Alanine-induced activation of MRGPRD leads to activation of G i/o and G q/11 proteins. KCNQ2/3 channels that conduct the important background M-current are inhibited by MRGPRD via G i/o and possibly G q/11 proteins. MRGPRD have been shown to elicit pruritogenic sensations and to contribute to normal mechanical and thermal pain thresholds. These distinct actions might be deployed by MRGPRD signaling in two distinct populations of primary sensory neurons. In blood vessels, MRGPRD are activated by the angiotensinogen metabolite alamandine. Signaling cascades that are engaged by alamandine include the endothelium-derived production of nitric oxide (NO) that leads to vasorelaxation.
TABLE 6 Pharmacology of human MAS-related G protein-coupled receptors X1
The potency of agonists is given as the EC 50 value to induce calcium signaling in the given cellular system and the potency of antagonists is given as the IC 50 value to inhibit BAM8-22-induced calcium signaling in the given cellular system. All data were generated after recombinant MRGPRX1 expression. MRGPRX1 share some pharmacological characteristics with rodent MRGPRC and MRGPRA subfamily members but also display unique pharmacological features. b. MAS-related G protein-coupled receptors X2. The MRGPRX2 subtype is clearly distinguishable from MRGPRX1 regarding its pharmacology (see Table 7 ), because MRGPRX2 do not bind BAM peptides (Burstein et al., 2006) . However, several other peptidergic ligands have been proposed in different heterologous or endogenous expression systems (Robas et al., 2003; Kamohara et al., 2005; Burstein et al., 2006; Tatemoto et al., 2006; Shemesh et al., 2008; Malik et al., 2009; Kashem et al., 2011; Liu et al., 2011; Subramanian et al., 2011a Subramanian et al., ,b, 2013 . The best characterized MRGPRX2 ligand is the cortistatin-14 peptide that activated MRGPRX2 with potencies in the medium to high nanomolar range (Robas et al., 2003; Kamohara et al., 2005; Burstein et al., 2006; Shemesh et al., 2008; Malik et al., 2009) . Notably, similar to MRGPRX1, the ligand binding profile of MRGPRX2 is conserved in rhesus monkeys, because cortistatin-14 also activates MRGPRX2 from this species (Burstein et al., 2006; Malik et al., 2009 ).
MRGPRX2 show a broader expression pattern than other MRGPRX, because MRGPRX2 expression was detected in primary sensory neurons, several brain areas, mast cells, and the adrenal medulla (Kamohara et al., 2005) . In line with this observation, proadrenomedullin peptides that endogenously occur as side products during adrenomedullin synthesis in the adrenal medulla have also been shown to activate MRGPRX2 (Kamohara et al., 2005) . MRGPRX2 were also shown to be involved in mast cell activation by a set of structurally similar, endogenous (Tatemoto et al., 2006; Subramanian et al., 2011a Subramanian et al., , 2013 or exogenous (Kashem et al., 2011; Subramanian et al., 2011b) basic secretagogues (see section III.G.2.d). Finally, in concordance with murine MRGPRC, the human PAR2-derived "SLIGKV"-peptide was shown to activate MRGPRX2 after expression in CHO cells at a concentration of 20 mM .
c. MAS-related G protein-coupled receptors X3 and -4. So far no study reported activation of MRGPRX3 and -4 by a given ligand. Therefore, data about signaling induced by MRGPRX3 and -4 or their biologic role are not available at present. For MRGPRX3 it has been shown that expression of this receptor subtype under control of the b-actin promoter in rats resulted in increased proliferation of lens fiber cells and keratinocytes in basal and suprabasal layers of the skin (Kaisho et al., 2005) . With regard to the MRGPRX4, a screening approach using human colorectal cancer cells revealed that the MRGPRX4 protein is one of 15 mutational hot spots in these cancer cells (Gylfe et al., 2013) . Thus, MRGPRX3 and -4 may behave as oncogenes in certain cancers.
2. Signaling Cascades and Physiologic Effects. a. Preface. MRGPRX1 and -2 function via activation of G proteins, as indicated by their ability to induce guanosine 59-O-(3-[ 35 S]thio)triphosphate incorporation into plasma membrane fractions (Kamohara et al., 2005; Burstein et al., 2006; Tatemoto et al., 2006) . Both receptors further induced the release of calcium from internal stores via PLCb-mediated production of inositol-1,4,5-trisphosphate (Lembo et al., TABLE 7 Pharmacology of human MAS-related G protein-coupled receptors X2
Potency of the ligand is given as the EC 50 value. The lowest concentration (LC) used to elicit a significant effect when measuring the respective readout is given. Data were generated after recombinant MRGPRX2 expression, despite when endogenous expression is indicated by "(e)". Robas et al., 2003; Breit et al., 2006; Solinski et al., 2012) . Different groups agree that activation of G q/11 proteins is involved in this process (Lembo et al., 2002; Robas et al., 2003; Kamohara et al., 2005; Breit et al., 2006; Burstein et al., 2006) . However, apart from its G q/11 coupling, additional coupling to PTX-sensitive G i/o proteins was described for MRGPRX1 (Chen and Ikeda, 2004; Gales et al., 2005; Burstein et al., 2006) or -2 (Kamohara et al., 2005; Subramanian et al., 2013) . According to their expression pattern, MRGPRX1 and -2 may be involved in somatosensory detector functions and plasticity of primary sensory neurons (see sections III.G.2.b and III.G.2.c) and in mast cell biology (see section III.G.2.d). However, despite specific expression, data highlighting MRGPRX2-mediated functions in primary sensory neurons are currently elusive. Moreover, MRGPRX2 may also induce hypotension and slow-wave sleep (see section III.G.2.e). Figures 7 and 8 give an overview of effects induced by MRGPRX1 or MRGPRX2, respectively.
Ligand
b. Somatosensory functions. To shape an organism's somatosensory performance, a GPCR needs to transfer stimuli detected in the skin into enhanced or reduced primary sensory neuron activity. Indeed, MRGPRX1 have been shown to modulate the activity of several distinct ion channels, thereby shaping neuronal activity. After heterologous expression in rat DRG, hippocampal, and superior cervical ganglion neurons, MRGPRX1 inhibited voltage-gated calcium channels, at least partly via PTX-sensitive G i/o proteins, leading to decreased synaptic transmission (Chen and Ikeda, 2004) . On the other hand, MRGPRX1 also inhibited M-type potassium channels via G q/11 proteins in the same cells, thereby relieving the neuron from a background potassium conductance that limits excitability (Chen and Ikeda, 2004) . In line with this notion, human MRGPRX1 induced action potentials after heterologous expression in murine DRG neurons (Liu et al., 2009) . The pain-enhancing TRPV1 might be involved in MRGPRX1-induced sensory neuron excitation, inasmuch as MRGPRX1 were shown to sensitize and directly activate this pain sensor (Solinski et al., 2012) . Interestingly, MRGPRX1 engaged TRPV1 via two distinct signaling pathways: sensitization took place via PKC-mediated phosphorylation of serine residues 502 and 800 of the channel, whereas direct TRPV1 activation relied on diacylglycerol binding to channel regions encompassing tyrosine 511 and phosphatidylinositol-3,4-bisphosphate (PIP 2 ) degradation. This multifaceted modulation of TRPV1 activity is unique among the GPCR superfamily (Chuang et al., 2001; Prescott and Julius, 2003; Woo et al., 2008; Kim et al., 2009; Solinski et al., 2012) and, thus, points to an important role of the TRPV1-MRGPRX1 regulatory axis in somatosensation.
The fact that MRGPRX1 were shown to either dampen or increase neuronal activity raises the question about the mechanisms responsible for these opposing effects. In this context it should be mentioned that distinct effects of MRGPRX1 on neuronal activity were observed in different cell types and that inhibition of neuronal activity apparently depends on G i/o and increased activity on G q/11 signaling. Because G protein coupling of a given GPCR might differ in distinct cell types (Hermans, 2003; Kukkonen, 2004) , distinct G protein coupling of the MRGPRX1 in different cells might be the most straightforward explanation for its opposing effects on neuronal activity. Because of the lack of endogenous model systems, effects of MRGPRX1 on neuronal activity have so far only been analyzed after overexpression of the MRGPRX1 protein also affecting its G protein coupling profile (Kenakin, 1997 (Kenakin, , 2006 . Thus, at this point it is not clear whether MRGPRX1 can act analgetically by decreasing neuronal activity under certain conditions and algetically by increasing neuronal activity in different circumstances. Alternatively, the receptors may even induce both effects at the same time, such that the net effect in a given cell would depend on which of the two signaling pathways dominates the other. It will be an important task for the future to analyze whether and how MRGPRX1 regulate the activity of primary sensory neurons of primates and, thus, nociception in vivo. These experiments are difficult to perform, because functional primary sensory neurons from humans are not available and rodents do not harbor MRGPRX1-encoding genes. However, rodent MRGPRC and human MRGPRX1 both bind BAM8-22, which has been shown to induce painenhancing, analgesic, and pruritogenic effects in mice or rats (see section III.D.2). Interestingly, in a seminal study in which BAM8-22 was applied to the skin of healthy human volunteers using cowhage spicules, acute itching accompanied by nociceptive sensations (pricking, stinging, and burning) was reported (Sikand et al., 2011) , thus showing that BAM8-22 acts similarly in rodents and humans and that MRGPRX1 function as somatosensory receptors with nociceptive and pruriceptive actions. However, because application by cowhage spicules is more likely to elicit itch compared with pain (Sikand et al., 2009 ), more work is needed to determine unequivocally if MRGPRX1 exert acute functions in pruriceptive and/or nociceptive primary sensory neurons in vivo.
c. Primary sensory neuron plasticity. Small-diameter primary sensory neurons respond to various acute or chronic stimuli, thereby showing high plastic changes in connectivity, morphology, or receptor expression pattern [see Woolf and Ma (2007) for further reading]. Interestingly, pathways that were implicated in adaptive responses of primary sensory neurons are well established players of proliferative signaling in dividing cells. One example is the extracellular signal-regulated kinase (ERK)-1/2 pathway that was implicated in adaptive responses of the 588 nociceptive system to chronic inflammation Wang et al., 2006a; Utreras et al., 2009; Su et al., 2010; Romero et al., 2012) .
Several indications point to the engagement of nuclear signaling pathways by MRGPRX, leading to transcriptional modulation. Overexpression of MRGPRX1 or -4 increased proliferation of 3T3 fibroblasts, highlighting considerable constitutive activity of these MRGPRX after recombinant expression (Burstein et al., 2006) . We recently found that after expression in primary sensory neuron-derived F11 cells, MRGPRX1 induced activation of ERK-1/2 and serum response element-dependent transcription as well as ERK-1/2-dependent expression of the immediate early genes c-Fos and early growth response protein 1 (Solinski et al., 2013) . Because of the published pathophysiologic importance of this pathway in rodents and humans Wang et al., 2006a; Utreras et al., 2009; Su et al., 2010; Romero et al., 2012) , MRGPRX1 may represent interesting targets in chronic inflammatory pain if this pathway is also activated by MRGPRX1 in vivo as well. 
MAS-Related G Protein-Coupled Receptors
It is interesting to mention that MRGPRX1 not only signal to the nucleus via classic proliferative pathways but also induced transcriptional alterations in primary sensory neurons via the calcineurin-dependent transcription factor nuclear factor of activated T cells (NFAT) (Solinski et al., 2013) . Activation of NFAT was already implicated in several plastic changes of primary sensory neurons, for instance axonal growth (Graef et al., 2003; Nguyen and Di Giovanni, 2008) and activity-dependent transcription (Groth et al., 2007; Jackson et al., 2007; Jung and Miller, 2008) . Moreover, BAM8-22-induced NFAT activation led to increased expression of chemokine receptors 2 (CCR2) in primary sensory neurons after recombinant MRGPRX1 expression (Solinski et al., 2013) . CCR2 were consistently found to be upregulated in primary sensory neurons under neuropathic conditions and to cause pain chronification (Abbadie et al., 2003; Sun et al., 2006; Bhangoo et al., 2007 Bhangoo et al., , 2009 White et al., 2007; Jung et al., 2009; Fu et al., 2010; Serrano et al., 2010; Wang et al., 2010) . Thus, MRGPRX1 may also be interesting targets in chronic neuropathic pain. d. Mast cell biology. Mast cells are long-lived mononuclear cells that reside in tissues near external surfaces, e.g., in skin or mucosa, and thereby are among the first cells of the immune system to respond to pathogens or allergens (Galli et al., 2011) . Mast cells fulfill their tasks in innate and adaptive immune responses by secretion of a plethora of mediators (degranulation), invaluable for host defense (Galli et al., 2011) . Mast cell degranulation is caused by IgE-dependent and -independent processes (Metcalfe et al., 1997; Ferry et al., 2002) . A very heterogeneous group of agents, either released endogenously by immune cells, neurons, and epithelial cells, or applied exogenously, mediates IgE-independent mast cell degranulation and is referred to as secretagogues (Sharma et al., 2002) . However, underlying signaling pathways are diverse and a matter of debate.
Endogenously expressed MRGPRX2 were proposed as receptors for different secretagogues in cultured human primary mast cells and in the differentiated human mast cell line LAD2 (Tatemoto et al., 2006; Kashem et al., 2011; Subramanian et al., 2011a Subramanian et al., ,b, 2013 . Early during infection, a first line of mast cell activation is thought to arise from complementmediated anaphylatoxin production (e.g., C3a or C5a) (Kashem et al., 2011; Subramanian et al., 2011b) . Although MRGPRX2 are not involved in mast cell activation provoked by endogenous anaphylatoxins, mast cell degranulation induced by a synthetic C5a receptor antagonist (PMX-53) or a C3a receptor superagonist (E7) required MRGPRX2 expression (Kashem et al., 2011; Subramanian et al., 2011b) . Later on during infection, epithelial cells can secrete b-defensins or cathelicidins, both inducing mast cell degranulation via MRGPRX2 (Subramanian et al., 2011a (Subramanian et al., , 2013 . Hence, MRGPRX2 can integrate paracrine input from various cell types by detecting alterations of the local milieu and inducing mast cell degranulation.
Degranulation of mast cells after MRGPRX2 activation depends on PTX-sensitive G proteins, irrespective of the MRGPRX2 ligand under investigation (Tatemoto et al., 2006; Kashem et al., 2011; Subramanian et al., 2011a Subramanian et al., ,b, 2013 . However, MRGPRX2 activation by LL-37 or human b-defensin-3 involves two different signaling cascades that act synergistically on degranulation, but only one of which depends on G i/o -induced PKC activation (Subramanian et al., 2011a (Subramanian et al., , 2013 . The second PTX-insensitive pathway involved calcium influx and release, as suggested by the inhibitory actions of the calcium release-activated calcium channel blocker, lathanium (La 3+ ), and the inositol 1,4,5-trisphosphate receptor and canonical TRP blocker, 2-aminoethoxydiphenyl borate (Subramanian et al., 2011a (Subramanian et al., , 2013 .
Because some basic secretagogues can be secreted by primary sensory neurons, MRGPRX2 may also enhance neuron-to-mast cell signaling, thereby shaping neuroimmune interactions. In congruence with this concept, MRGPRX1 were implicated in the secretion of chemokine ligand 2 from LAD2 mast cells after stimulation with BAM8-22 (Solinski et al., 2013) . Given that MRGPRX1 induced the expression of the chemokine ligand 2 receptor CCR2 in primary sensory neurons (Solinski et al., 2013) , it is appealing to hypothesize that MRGPRX1 could additionally enhance mast-cell-to-neuron signaling. Because mast cells contribute to chronic pain (Zuo et al., 2003) , inhibition of such a paracrine signaling circuit would be an interesting approach for future analgesic therapy.
e. Putative role of MAS-related G protein-coupled receptors X2 in sleep and blood pressure regulation. PAMP1-20 is a potent hypotensive peptide, functioning mainly via inhibition of norepinephrine and epinephrine release from sympathetic neurons or adrenal chromaffin cells, respectively (Shimosawa et al., 1995; Kobayashi et al., 2001) . On the protein level, PAMP1-20 is mainly distributed in adrenal medulla and atrium (Washimine et al., 1994) . Because MRGPRX2 proteins have been detected in adrenal chromaffin cells and because PAMP1-20 activated MRGPRX2 in heterologous expression systems, Kamohara and coworkers (2005) proposed that epinephrine-dependent hypotensive functions of PAMP1-20 might be mediated by MRGPRX2 signaling.
Cortistatin-14 activates all five somatostatin receptor (SSTR1-5) subtypes, but some effects of cortistatin-14 appear to be clearly independent of these receptors and are not caused by somatostatin (de Lecea, 2008) . Among these effects is the induction of slow-wave sleep that might be partly mediated by inhibition of hippocampal neurons. Because MRGPRX2 are expressed in hippocampal neurons of layer CA2-4 and because MRGPRX2 responded specifically to cortistatin-14, Robas and coworkers (2003) put forward the proposal that MRGPRX2 may be involved in cortistatin-14-mediated slow-wave sleep induction.
IV. Agonist-Promoted Internalization and
Desensitization of MAS-Related G Protein-Coupled Receptors GPCR signaling is commonly regulated by agonistinduced receptor phosphorylation that leads to uncoupling from cognate G proteins (desensitization) and subsequent receptor internalization (endocytosis), mostly via association with b-arrestins (Ferguson, 2001 ). In addition, b-arrestins have been shown to induce G protein-independent signaling pathways, further increasing the repertoire of GPCR-mediated signaling (Shenoy and Lefkowitz, 2003) . Only a few GPCR have been shown to resist agonist-promoted processes that negatively regulate receptor activity, including k-OR, MAS-Related G Protein-Coupled Receptors b 3 -adrenoceptors, and SSTR4 (Nantel et al., 1993; Chu et al., 1997; Csaba and Dournaud, 2001) .
Detailed analysis of the subcellular distribution of human MRGPRD fused to green fluorescent protein (GFP) in CHO cells after a 30-minute period of stimulation with saturating concentrations of b-alanine (Shinohara et al., 2004) revealed translocation of the receptor protein from the plasma membrane to punctate intracellular vesicles, indicative of ligand-induced internalization. Dose-dependent internalization of c-myc-tagged rat MRGPRD by b-alanine after recombinant expression in HEK293 cells was also identified, using either a qualitative immunofluorescence or a quantitative enzyme-linked immunosorbent assay approach (Milasta et al., 2006) . Thus, MRGPRD, the only MRGPR conserved in rodents and primates and assigned to an agonist, apparently belongs to the group of endocytosis-prone GPCR.
After recombinant expression of murine MRGPRA1 or MRGPRA4 in HEK293 cells, Dong and coworkers (2001) observed a prominent decline in ligand-induced calcium signals after repetitive short term stimulation with FLRFamide or NPAF, indicating agonistpromoted desensitization. Desensitization was reversible by ligand wash-out over ;20 minutes and most likely occurred because of phosphorylation and endocytosis of the respective receptor protein. In fact, in HEK293 cells murine MRGPRA1 fused to GFP was internalized to punctate intracellular vesicles after 30 minutes of agonist stimulation (Han et al., 2002) .
Likewise, MRGPRC-GFP fusion proteins also internalized after 30 minutes of stimulation by saturating concentrations of g 2 -MSH in HEK293 cells (Han et al., 2002) . This work was corroborated by the finding that 1) other full agonists of murine MRGPRC including BAM8-22 are able to induce the same extent of MRGPRC endocytosis; 2) endocytosis is not confined to HEK293 cells, but also detectable in several DRG neuron-derived cell lines; 3) b-arrestins are indispensable for proper ligand-induced MRGPRC endocytosis in Cos7 cells (Solinski et al., 2010) . Notably, rat MRGPRC was also found to be sensitive to BAM8-22-or g 2 -MSH-induced endocytosis in the same cell models (Solinski et al., 2010) . In sharp contrast to rodent BAM8-22-sensitive MRGPRC, human MRGPRX1 resisted BAM8-22-induced desensitization and endocytosis after recombinant expression in different cellular systems, including primary sensory neuronderived F11 and ND-C cells (Solinski et al., 2010) . Thus, identical ligands regulate MRGPRC and MRGPRX1 endocytosis in diametrically opposed ways. Moreover, similar to MRGPRX1, ligand-induced phosphorylation and internalization of the MRGPRX2 was not detectable (Subramanian et al., 2011a) . Thus, absence of agonistpromoted receptor desensitization appears as a common feature among MRGPRX, defining the MRGPRX subfamily as the first among all GPCR families to harbor more than one endocytosis resistant member. Whether MRGPRX3 and -4 also resist agonist-mediated desensitization still needs to be confirmed in the future. Notably, serine residues in the C-terminal tail of a given GPCR are profoundly involved in agonist-induced receptor regulation (Ferguson, 2001 ) and, as already mentioned, C-terminal tails of MRGPRX developed under strong positive selection pressure during evolution. It is tempting to speculate that considerable physiologic benefits have been earned by enriching the lack of receptor desensitization and endocytosis among MRGPRX. A summary of the available literature analyzing ligand-induced regulation of MRGPR is given in Table 8 . Heteromultimerization among GPCR has been proposed to alter ligand binding, G protein coupling, protein trafficking, and agonist-promoted desensitization of the receptors involved (Bulenger et al., 2005) . Thus, direct protein-protein interactions due to receptor multimerization represent an important mechanism by which distinct hormone systems interact with each other (Jordan et al., 2001; Torvinen et al., 2005; Parenty et al., 2008) . Because MRGPRX1 and OR share a common ligand, the BAM1-22 peptide, are coexpressed in primary sensory neurons, and both affect pain modulation, functional interactions between MRGPRX1 and the d-OR (DOP) due to multimerization have been analyzed. Bioluminescence resonance energy transfer experiments revealed that MRGPRX1 interacted with human DOP in living HEK293 cells stably overexpressing each receptor (Breit et al., 2006) . Individual activation of either DOP (with Leu-Enkephalin) or MRGPRX1 (with BAM8-22) allowed both receptors to modulate their respective signaling pathways. In contrast, the DOP/ MRGPRX1 bivalent agonist BAM1-22, which activated each receptor expressed individually, fully activated the MRGPRX1 but did not promote DOP-mediated signaling within the heteromultimer. Similarly, concomitant activation of the DOP/MRGPRX1 heteromultimer by selective DOP and MRGPRX1 agonists (LeuEnkephalin and BAM8-22) promoted MRGPRX1 but not DOP signaling. Furthermore, coexpression of the endocytosis resistant MRGPRX1 inhibited agonistpromoted internalization of the endocytosis-prone DOP. Overall, these data suggest that MRGPRX1 signaling within the DOP/MRGPRX1 heteromultimer acts in a dominant-negative fashion on DOP signaling 592 and thus, could affect the fine tuning of pain sensation regulated by DOP.
MRGPR have not only been shown to interact with members of other GPCR families, but also among each other. The rat MRGPRD and -E subtypes form multimeric complexes when expressed in HEK293 cells or peripheral nociceptive neurons, as previously indicated by coimmunoprecipitation and time-resolved fluorescence resonance energy transfer (Milasta et al., 2006) . These interactions increased the potency of b-alanine to phosphorylate ERK-1/2, maintained the capacity of b-alanine to elevate intracellular calcium concentrations, and inhibited b-alanine-induced internalization of MRGPRD. Given the large number of MRGPR family members and assuming that heteromultimeric interactions also exist between other subtypes, one would predict an immense variety of putative binding sites for MRGPR-selective ligands, expanding the impact of this receptor family on many physiologic pathways even further.
B. Inhibition of Tolerance to Morphine
As mentioned above, BAM-sensitive, human MRGPRX1 functionally interact with the opioid system based on receptor multimerization. Interestingly, multimerization-independent interactions between BAM-sensitive MRGPRC and opioid receptors have also been described in vivo. A major problem of chronic pain treatment with morphine is the development of tolerance characterized by declining analgesic effects after repeated dosing. The mechanisms that cause the underlying adaptation processes are manifold and not completely understood [for further reading see Williams et al. (2013) ]. In rats, tolerance to morphine can be generated by its daily application over six to seven days. Interestingly, after intrathecal application of MRGPRC-specific agonists in rats, morphine regained ;50% of its analgesic actions in formerly morphinetolerant animals on the consecutive day (Jiang et al., 2006; Cai et al., 2007b; Chen et al., 2010b) . MRGPRC agonists were not only able to restore analgesic efficacy after tolerance to morphine had already been established, intrathecally applied BAM8-22 or Tyr 6 -g 2 -MSH6-12 on every second day during induction of morphine tolerance dose-dependently inhibited the development of morphine tolerance (Cai et al., 2007b; Chen et al., 2010b) . Compensatory upregulation of painenhancing molecular players in the DRG and spinal cord including PKCg-dependent upregulation of nNOS or CGRP is involved in the development of morphine tolerance (Menard et al., 1996; Kolesnikov et al., 1997; Granados-Soto et al., 2000) . Because MRGPRC agonists blocked enhanced PKCg activity in the spinal cord and diminished nNOS and CGRP immune reactivity in DRG and spinal cord slices, this signaling cascade might inhibit morphine tolerance by MRGPRC (Chen et al., 2010b) .
VI. Conclusions and Perspectives
Over the last decade, our knowledge about MRGPR has been significantly extended: 1) the murine MRGPRA3 subtype has been identified as the itchmediating chloroquine receptor; 2) rodent MRGPRC have also been shown to be involved in itching and MRGPRC have been made responsible for analgesic and pain-enhancing effects; 3) MRGPRD enhance neuronal excitability and induce vasorelaxation; and 4) human MRGPRX also modulate excitability of primary sensory neurons and gene expression in these cells. However, because of the lack of suitable model systems, these data are solely based on experiments obtained after heterologous expression of the MRGPRX1 protein. In mast cells, endogenously expressing the MRGPRX1 and -2 subtype effects on degranulation and mediator release have been found. Adaptive evolutionary development and resistance to agonistpromoted desensitization/endocytosis further highlight the extraordinary features of the primate-specific MRGPRX subfamily. Notably, MRGPRX can be considered as valuable drug targets with low or even no offtarget effects because of their restricted expression in primary sensory neurons and mast cells.
However, our knowledge about the MRGPR family is still superficial and central questions need to be addressed: 1) to what extent do MRGPR serve as markers for primary sensory neurons that execute specific functions; 2) what is the difference between distinct rodent species in this regard; 3) what is the physiologic role of distinct MRGPR in these specialized neurons? Consider, in particular, that some subtypes of the MRGPRA and -X subfamilies are not yet analyzed, mainly because not a single ligand for these receptors is available. Similarly, progress in the work with MRGPRE to -H receptors is significantly hindered by the lack of agonists. Moreover, it will be essential to define the signaling events responsible for the effects of MRGPRC agonists on nociception. Interestingly, human MRGPRX1 have been shown to enhance or inhibit signaling pathways that supposedly modify neuronal activity, suggesting that MRGPRX1 might also exert proalgetic and analgesic effects in humans. In this context it will be important to analyze to which extent data obtained from BAM8-22-sensitive rodent MRGPRC can be extended to BAM8-22-sensitive human MRGPRX1. Convincing evidence that rodents can in fact be used as a native model systems for human BAM8-22-sensitive MRGPRX1 would propel the "deorphanization" process of these receptors forward and would simplify the development of drugs tested in established animal models but intended to target human MRGPRX1. In parallel, it would be of interest to develop primate-or even human-based DRG-derived cell models that endogenously express MRGPRX1. Considering mast cells, a step forward has been made at this point, because the human mast cell line LAD2 has been shown to endogenously express MRGPRX1 and -2. Furthermore, the problem of ligand-sharing between MRGPR and subtypes of other GPCR families, observed for many endogenous ligands (see Table 9 ), is a major drawback in the field. Thus, screening efforts yielding MRGPR subtype-specific agonists and antagonists would significantly help attain a better understanding of the physiologic pathways engaged by MRGPR in vivo.
